Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF

Back

ESC Professional Premium Access

Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF

Session: Insights from recent HFpEF trials 1

Topic: Pharmacotherapy

Speaker: Professor B. Pitt (Ann Arbor, US)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Bertram Pitt

University of Michigan, Ann Arbor (United States of America)

24 presentations

0 follower

5 more presentations in this session

Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial

Speaker: Doctor S. Chatur (Boston, US)

Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

Speaker: Doctor X. Wang (Boston, US)

Dietary sodium intake and outcomes: a secondary analysis from SODIUM - HF

Speaker: Professor C. Saldarriaga Giraldo (Medellin, CO)

Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction

Speaker: Doctor M. Pabon (Boston, US)

Effects of empaglifozin on collagen biomarkers in patients with heart failure. Results from the EMPEROR trials

Speaker: Doctor M. Sumin (Mainz, DE)

Access the full session

Insights from recent HFpEF trials 1

Speakers: Professor B. Pitt, Doctor S. Chatur, Doctor X. Wang, Professor C. Saldarriaga Giraldo, Doctor M. Pabon...

Access

Video

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources